As of 2025-06-03, the Intrinsic Value of Beijing Tong Ren Tang Chinese Medicine Co Ltd (3613.HK) is 12.47 HKD. This 3613.HK valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 8.58 HKD, the upside of Beijing Tong Ren Tang Chinese Medicine Co Ltd is 45.40%.
The range of the Intrinsic Value is 10.50 - 15.85 HKD
Based on its market price of 8.58 HKD and our intrinsic valuation, Beijing Tong Ren Tang Chinese Medicine Co Ltd (3613.HK) is undervalued by 45.40%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 10.50 - 15.85 | 12.47 | 45.4% |
| DCF (Growth 10y) | 12.96 - 19.92 | 15.54 | 81.1% |
| DCF (EBITDA 5y) | 9.85 - 11.24 | 10.25 | 19.5% |
| DCF (EBITDA 10y) | 11.88 - 14.17 | 12.70 | 48.0% |
| Fair Value | 2.99 - 2.99 | 2.99 | -65.17% |
| P/E | 5.58 - 8.07 | 6.58 | -23.3% |
| EV/EBITDA | 5.57 - 7.77 | 6.81 | -20.6% |
| EPV | 12.46 - 16.53 | 14.49 | 68.9% |
| DDM - Stable | 5.62 - 12.37 | 9.00 | 4.9% |
| DDM - Multi | 9.73 - 16.41 | 12.20 | 42.2% |
| Market Cap (mil) | 7,182.32 |
| Beta | 0.76 |
| Outstanding shares (mil) | 837.10 |
| Enterprise Value (mil) | 5,532.67 |
| Market risk premium | 5.98% |
| Cost of Equity | 6.39% |
| Cost of Debt | 4.25% |
| WACC | 6.35% |